Dr. Georg Lautscham, CBO, is a chemist and immunologist by training. He has over 12 years experience and expertise in clinical research, business development, strategic alliance management and general management from the CRO and Biotech industry. He joined Protagen in 2013.
Dr. Peter Schulz-Knappe is CSO of the company, being a MD and cell biologist by training. He brings over 25 years of protein and peptide biochemistry, biomarker discovery & development experience, as well as 15 years of management experience in R&D, gained while CEO and CSO at BioVisioN and as CSO at Proteome Sciences. He joined Protagen in 2010.
Board of Directors
Dr. Bernhard Kirschbaum (Chairman) is an independent advisor. He was head of Global Research and Early Development and member of the Executive Committee at Merck-Serono. Dr. Kirschbaum has a long standing track record in pharma R&D and held various executive positions at Hoechst, Aventis, Sanofi, and Merck.
Dr. Dirk H. Ehlers is President and CEO of Trumpf Medical (Hill-Rom Group). Previously he was CEO of Eppendorf AG and over the past 20 years held various senior positions within the life science industry, notably with Roche Diagnostics, Evotec, Fresenius Kabi and Olympus Diagnostics.
Wolfgang Kintzel heads the Life Sciences & CleanTech Venture Capital activities at the NRW.BANK in Duesseldorf. Mr. Kintzel held various executive positions within the European and US Life science industry at Schering AG, Mallinckrodt Medical B.V., Tyco Inc. and amaxa AG.
Matthias Guth is Venture Partner of MIG Funds and active in Venture Capital since more than 15 years. He is Founder and Managing Director of Matthias Guth Corporate Finance GmbH, prior to this he was with Wellington Partners and goetzpartners.
Oliver Schacht, PhD is CEO of Curetis N.V. (Euronext: CURE) a molecular diagnostics company active in hospital infections. He was previously CEO of epigenomics Inc. (Seattle, USA) and CFO of epigenomics AG (Germany) and has co-founded several technology companies in Europe and the US.